Peninsula startup lands $30 million for vaccine targeting deadly infant infection

A South San Francisco company landed a $30 million investment to take an experimental vaccine into clinical trials against a deadly virus in infants and the elderly. Meissa Vaccines Inc., launched five years ago by a former Emory University researcher Marty Moore and ex-MedImmune scientist Roderick Tang, landed the cash in a Series A financing by Morningside Ventures to develop a longer-lasting, universal vaccine against respiratory syncytial virus. RSV is be st known for causing pneumonia and inflaming…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news